Biotech In Europe Investor Forum 2003 Exhibitor Profiles.

Business Editors/Health/Medical Writers

BIOWIRE2K

Biotech In Europe Investor Forum 2003

MUNICH, Germany--(BUSINESS WIRE)--Oct. 2, 2003

The 3rd Annual Biotech In Europe Investor Forum takes place Nov. 5 - 6 at the Hilton Munchen Park in Munich, Germany. For in-depth information about the Forum visit http://www.sachsforum.com/mebio2003_fs.html.

Below are profiles from Biotech In Europe Investor Forum exhibitors. News releases and advisories are available at http://www.tradeshownews.com, Business Wire's trade show and conference news resource. Business Wire is the official news wire service for the Biotech in Europe Investor Forum.

Company: ACE BioSciences
Public Relations Contact: Kamilla Reng
Investor Relations Contact: Ejvind Mortz
Phone: [phone]
E-mail: [e-mail]
Web Address: www.acebiosciences.com

ACE BioSciences is a biotechnology company focused on the discovery,
pre-clinical and early clinical development of new drug targets and
drug leads for better treatment of infectious diseases caused by
pathogenic microorganisms. The integrated target discovery platform at
ACE BioSciences is developed for high-throughput infectious disease
target discovery and the whole workflow; laboratory set-up, database
structures, proteomic, bioinformatic and biology tools are designed
and integrated for this specific purpose. The platform is unique of
its kind and no other company is able to apply the integrated
proteomic approach we use to study pathogenicity mechanisms in
bacterial organisms.

Company: Amarin Corporation
Public Relations Contact: Jane Powel
Investor Relations Contact: Thomas Fechtner
Phone: [phone]
E-mail: [e-mail]
Web Address: www.amarincorp.com

Amarin Corporation is a specialty pharmaceutical company focused on
neurology, initially targeting the niche sectors of Parkinson's
disease, Huntington's disease and other neurological movement
disorders which have significant unmet medical needs. Amarin's
franchise in Parkinson's disease includes one established treatment
with another promising late-stage candidate in development. Amarin
also has an exciting potential treatment for Huntington's disease in
late stage development. Huntington's disease is a fatal
neurodegenerative disorder for which there is currently no treatment
available. The company currently markets, throughout the US, a
portfolio of branded growth products included in a group of products
acquired in 1999 from Elan. It also operates a European based product
development division. Although Amarin is headquartered in the UK, its
main operation is in the US and its primary listing is on NASDAQ.

Company: AMT B.V.
Public Relations Contact: Jan Boesen, Ph.D.
Investor Relations Contact: Robert Ranzijn
Phone: [phone]
E-mail: [e-mail]
Web Address: www.amtbv.com

AMT's mission is to be successful in the development and production of
virus-based therapeutics and vaccines. To date the company has grown
to 33 employees. AMT's lead product is LPL gene therapy for the
treatment of LPL deficiency. This inherited, often fatal, disease
results in the accumulation of triglycerides and consequently multiple
organ failures. Preclinical studies in LPL deficient mice and cats
demonstrated a greater than 95% decrease of triglyceride levels. The
first patients are planned to be treated mid 2004 with market
introduction of LPL gene therapy in 2007. Besides, AMT is developing
therapies for the treatment of Crohn's disease and Familial
Hypercholesterolemia. AMT is offering GMP manufacturing services on a
fee-for-service basis.

Company: Androclus Therapeutics
Public Relations Contact: Dr. Lorenzo Boscarelli
Investor Relations Contact: Dr. Lorenzo Boscarelli
Phone: U.S. [phone] Europe: [phone]
E-mail: [e-mail]
Web Address: www.androclus.com

Androclus Therapeutics (AT) has the mission to discover, develop, and
bring to commercial fruition novel compounds to treat diseases
involving the immune system, such as autoimmunity, cancer and
infections. The discovery of new leads is based on original and
proprietary technologies able to identify compounds with
immunomodulatory, rather than immunosuppressive activity. One of AT's
compounds is undergoing Phase II trial in rheumatoid arthritis in the
U.S.; it was licensed to Serono in early 2003. AT is also committed to
the treatment of multiple sclerosis, inflammatory bowel disease, and
to a novel approach to cell therapy for infections in
immuno-compromised patients.

Company: Arakis Ltd
Public Relations Contact: Ken Cunningham
Investor Relations Contact: Ken Cunningham
Phone: [phone]
E-mail: [e-mail]
Web Address: www.arakis.com

Arakis is an emerging specialty pharmaceutical company, with a
commercial focus in rheumatology and oncology adjunctive therapy. It
possesses a unique research capability specialising in cytokine and
receptor mediated mechanisms of disease. The Company identifies,
develops and commercialises product opportunities based upon new
clinical uses for known drugs, or known drug templates, termed
Performance Enhanced Medicines (PEMs). Arakis has four full
development projects - three clinical and one preclinical - two
exploratory developments and research programmes within the areas of
pain, emesis and rheumatology. These are all directed to areas of
significant unmet medical need.

Company: Arpida Ltd.
Public Relations Contact: Harry Welten
Investor Relations Contact: Harry Welten
Phone: [phone]
E-mail: [e-mail]
Web Address: www.arpida.ch

Arpida Ltd. is dedicated to the discovery and development of novel and
more efficacious anti-microbial drugs for the prevention or treatment
of serious infectious diseases. The company has a balanced portfolio
of clinical and development compounds, novel chemical leads and
several proprietary assays in high throughput format for lead
discovery. The most advanced compound is in clinical trials and will
be developed for the treatment of severe infections caused by Gram
positive pathogens. Moreover, the company has identified several lead
molecules with novel mechanisms of action from six discovery programs.
Arpida uses an integrated multidisciplinary approach to drug-discovery
and development, using genomics-assisted selection of target, high
throughput screening for identification of novel leads, and parallel
synthesis for rapid lead optimization. Currently, the company has a
total staff of 40 (17 Ph.D.'s).

Company: Artesian Therapeutics
Public Relations Contact: Brandon Lewis
Investor Relations Contact: Brandon Lewis
Phone: [phone] x 15
E-mail: [e-mail]
Web Address: www.artesianrx.com

Artesian Therapeutics, Inc is a privately-held biopharmaceutical
company founded in March of 2002, to discover and develop the first
generation of disease modifying and disease reversing therapeutics for
the treatment of cardiovascular disease. Artesian currently has two
advanced small molecule discovery programs in the area of disease
progression during congestive heart failure (CHF). Artesian has
selected a lead compound from its CRPM program, ATI 22-107, and is on
track for filing an IND in 4Q04. Selection of a lead compound for
preclinical development from Artesian's BRPM program is on track for
1Q04 with an IND filing in 1Q05.

Company: atugen AG
Public Relations Contact: Thomas Christely
Investor Relations Contact: Thomas Christely
Phone: [phone]
E-mail: [e-mail]
Web Address: www.atugen.com

atugen AG, a German biopharmaceutical company, was founded November
1998 with the focus to identify novel drug targets and drug candidates
that drive the molecular pathology and development of cancer. atugen's
technologies, in particular the target validation capabilities and
proprietary gene expression Knock-Down ("gene silencing") tools, are
used to elucidate disease-specific signal transduction pathways.
atugen has already proven the value of its technologies and expertise
by establishing a portfolio of novel functionally validated targets
and compounds inhibiting an important biological pathway - the
phosphatidyl-inositol 3-OH kinase (PI 3-K) pathway. This pathway plays
an important role in most cancer types, diabetes, wound healing and
other indications. atugen's leading role in disease-specific pathway
elucidation is further underlined by its collaborations with
high-profile pharmaceutical and biotechnology companies.

Company: Avidex Limited
Public Relations Contact: Kirstin Brimsted
Investor Relations Contact: James Noble
Phone: [phone]
E-mail: [e-mail]
Web Address: www.avidex.com

Avidex's protein and small molecule products include: Monoclonal TCRs
that can target anti-cancer agents to tumours or block activation of T
cells in autoimmune diseases. An orally active small molecule CD80
antagonist that acts as a gentle immune suppressor. Avidex focuses on
the development of products based on molecules that present themselves
at the T cell interface. Through our knowledge and understanding of T
cells, Avidex is able to manipulate the key components of T cell
activation. As a private company, headquartered in Oxford, UK, Avidex
has 55 employees.

Company: AVONTEC GmbH
Public Relations Contact: Dr. Thomas Schulze
Investor Relations Contact: Dr. Thomas Schulze
Phone: [phone]
E-mail: [e-mail]
Web Address: www.avontec.de

AVONTEC GmbH is a biopharmaceutical company based in Gottingen,
Germany, whose primary focus is developing a new class of DNA-based
therapeutics showing superior cellular up-take by utilizing its
proprietary transcription factor decoy technology in the area of
chronic inflammatory diseases. AVONTEC aims at improved
next-generation antiinflammatries with a safety/efficacy profile
superior to inhaled and topical steroids with a first product in phase
I/IIa studies(asthma), followed by a second in November 2003
(psoriasis). AVONTEC has a first corporate partnership with the
Berlin-based medical device manufacturer on the development of
next-generation drug-eluting stents and won the prestigious German
Founders Award.

Company: Borean Pharma A/S
Public Relation: Inger Plejdrup
Phone: ++45 8620 5046
Email: [e-mail]
Investor Relation: Dr. Riku Rautsola
Phone: ++45 8620 5145
Email : [e-mail]
Web address : www.boreanpharma.com

Borean Pharma was established with the objective to develop a new
generation of pharmaceutical protein products. The company's
competitive advantage lies in its proprietary technology, enabling it
to develop a new generation of highly efficacious antibody-analogues
that can be produced in E.coli. The ease of production addresses a
major short-coming of monoclonal antibodies. Borean believes that it
can unleash the true potential of biologicals by providing efficacious
and cost-effective protein-based antibody-analogues. Borean focuses on
indications and targets respectively, for which biologicals have
already a proven track record and significant sales as drugs,
decreasing the development risk. The company operates on a business
model that is based on early outlicensing, which will enable Borean to
break-even as early as 2007.

Company: Chiral Quest
Public Relations Contact: Tim Hurley
Investor Relations Contact: Thomas Fechtner
Phone: + 1(814)234-5054
E-mail: [e-mail]
Web Address: www.chiralquest.com

Chiral Quest is a research-based, life sciences chemistry company
dedicated to providing asymmetric products, technology and services to
the pharmaceutical/biotechnology and fine chemical industries. Its
array of catalysis products and technology services, based on
proprietary catalytic expertise, is designed to facilitate the
development of chiral molecules, which comprise over one-third of all
drugs currently on the market. Chiral Quest aims to become a leading,
high value technology provider and partner in the chiral therapeutics
industry by offering proprietary catalysts, novel chiral building
blocks, and collaborative synthetic solutions applied to the chiral
area.

Company: CombinatoRx, Inc.
Public Relations Contact: Adeeb Mahmud
Investor Relations Contact: Daniel Grau
Phone: [phone]
E-mail: [e-mail]
Web Address: www.combinatorx.com

CombinatoRx is creating new combination medicines that attack disease
on multiple fronts. The company has an impressive clinical and
preclinical pipeline of novel agents, including treatments in
development for cancer and rheumatoid arthritis, and has ongoing
research in respiratory, metabolic, and infectious diseases.
CombinatoRx invented the industry's first combination drug discovery
platform to generate new medicines, based upon new insights into
disease networks, in a broad range of therapeutic areas. Founded in
2000 by scientists from Harvard and MIT, the company has raised $60M
in venture capital and is executing on its business strategy to
rapidly build and commercialize a portfolio of breakthrough products.

Company: Cyclacel Limited
Public Relations Contact: Spiro Rombotis
Phone: [phone]
E-mail: [e-mail]
Web Address: www.cyclacel.com

Cyclacel - a biopharmaceutical company that designs and develops small
molecule drugs that act on key cell cycle regulators to stop
uncontrolled cell division in cancer and other diseases involving
abnormal cell proliferation. The Company's discovery engines integrate
cell cycle biology expertise with a large library of proprietary
gene-based targets, state-of-the-art RNAi functional genomics,
chemogenomics and clinical biomarker technologies to rapidly deliver
new drugs. Six research and development programs are underway. Most
advanced is CYC202, a Cyclin Dependent Kinase (CDK) inhibitor, in
Phase IIa trials. Corporate alliances in oncology entered into with
AstraZeneca, CV Therapeutics and top 5 pharmaceutical major.

Company: Cytochroma Inc.
Public Relations Contact: Dr. Robert Foldes
Investor Relations Contact: Dr. Robert Foldes
Phone: [phone] ext. 314
E-mail: [e-mail]
Web Address: www.cytochroma.com

Cytochroma Inc. is a small-molecule drug discovery and development
company focused on treating skin disorders and cancer by targeting a
family of proteins termed cytochrome P450s (CYP). Cytochroma currently
has four preclinical programs. CTA018, a CYP24 inhibitor, has been
selected as an IND candidate for mild to moderate psoriasis with an
IND application expected to be filed in late 2004. CYP26A/B inhibitors
are being developed through a partnership with Allergan, Inc.
Cytochroma is a privately-held company and has raised over US$16
million in equity financing to date. Cytochroma is preparing for a
series "C" private placement in 2004/2005.

Company: DeveloGen AG
Presentation by Dr. Gunther Karmann
Media Contact: Dr. Susanna Braus-Stromeyer
Investor Relations Contact: Carsten Dehning
Phone: [phone]
E-mail: [e-mail]
Company URL: www.develogen.com

DeveloGen is a biology based drug discovery company developing novel
therapies for metabolic disorders based on extensive model organism
and stem cell expertise. By starting with metabolic phenotype, the
company's model organism screens are more rapid and disease relevant
than conventional functional genomics methods. The second component of
DeveloGen's platform is focused on harnessing key developmental
control genes involved in stem cell differentiation and tissue
regeneration. By combining the strengths of two platform technologies,
DeveloGen has established a pipeline of more than 30 highly validated
targets for obesity and diabetes. Based on this broad target pipeline,
DeveloGen and Evotec OAI entered recently into a joint drug discovery
and development partnership.

Company: EUROPROTEOME AG
Public Relations Contact: Walter von Horstig PhD
Investor Relations Contact: Walter von Horstig PhD
Phone: +49 - 3302 - 202 3253
E-mail: [e-mail]
Web Address: www.europroteome.com

EUROPROTEOME - the Human Cancer Company - is a product-focused
biopharmaceutical company with an associated network of oncology
experts. The company is dedicated to leveraging its unique human
molecular and comprehensive clinical data for novel inroads for the
treatment of epithelial cancer patients. EUROPROTEOME's mission is to
provide the oncology market with novel therapeutic, diagnostic, and
prognostic products, which are based on its proprietary
cancer-associated (e.g. validated) and drugable disease targets &
markers. EUROPROTEOME's vision is to become a preferred product
development partner for leading pharmaceutical and diagnostic
companies. EUROPROTEOME applies proteome technology to human
epithelial cancers in order to identify specific gene expression
patterns (targets / markers). EUROPROTEOME operates a state-of-the-art
high throughput proteomics and gene expression laboratory in the
Biotech Park at Hennigsdorf/Germany (near Berlin). EUROPROTEOME has
set up one of the world's largest human tumor sample banks and cancer
networks consisting of clinical and scientific researchers from
several European research institutes and clinics. EUROPROTEOME's
patented sample preparation method provides a unique source for highly
purified human tissue samples. In combination with a well-standardized
set of patient data EUROPROTEOME has a privileged starting position
for a leading position in the oncology market.

Company: Favrille, Inc.
Public Relations Contact: Tamara A. Seymour
Investor Relations Contact: John Longenecker
Phone: [phone]
E-mail: [e-mail]
Web Address: www.favrille.com

Favrille has developed a proprietary technology platform that utilizes
unique characteristics of each patient's disease to generate
patient-specific therapeutic vaccines for treatment of cancer and
autoimmune disease. The major barrier to the commercialization of
these therapies is cost of production. Favrille's production process
is significantly less expensive than other methods. In April of 2002,
the Company closed a $16.9 million Series B Preferred Stock offering.
These funds are being used to complete enrollment of the current
B-cell lymphoma Phase II trials and to initiate additional clinical
trials. The Company raised $10.6 million in the first closing of
Series B-2 in June 2003. The financing will remain open to new
investors through September 2003 for up to an additional $10 million.
FavId(TM) (Favrille's patient-specific therapeutic vaccine for
follicular, B-cell non-Hodgkin's lymphoma) is created following the
identification, production and manipulation of tumor-specific
"idiotype" proteins. These idiotype-proteins are presented to the
patient in the context of a strong immune stimulating agent, KLH. Most
patients mount an idiotype-specific immune response that appears
capable of destroying tumor cells. The Company is conducting Phase II
clinical studies in the U.S.

Company: Gamida-Cell Ltd.
Public Relations Contact: Marjie Hadad
Investor Relations Contact: Ehud Marom
Phone: [phone]
E-mail: [e-mail] / [e-mail]
Web Address: www.gamida-cell.com

Gamida-Cell Ltd. (www.gamida-cell.com) is a leader in the expansion of
hematopoietic (blood) stem cell therapeutics in clinical development
for cancer and autoimmune diseases, as well as future regenerative
cell-based medicines. The company is currently recruiting patients for
an IND Phase I study of its flagship product StemEx(R) for the
treatment of leukemia and lymphoma. The study is taking place at M. D.
Anderson in Texas and will directly be followed by a pivotal
multi-center study in the US and Europe. The Company's first
commercial product is expected in 2006. Gamida-Cell is also one of the
leaders of the newly established Israel Stem Cell Therapy Consortium
purposed to combine the efforts of companies, academic groups and
hospital research centers to develop generic technologies for
industrialized stem cell therapy. Gamida-Cell, which has an existing
strategic agreement in place with TEVA following an equity investment
by the pharmaceutical giant, is currently focused on establishing
partnerships with those in the global biotech and business communities
interested in collaborating on the development of effective and
therapeutic treatments for cancer, cardiac, diabetic, neural, liver
and skin indications, a market estimated to be approximately $30
billion.

Company: LifePoint, Inc. (AMEX: LFP),
Public Relations Contact: Linda H. Masterson
Investor Relations Contact: Linda H. Masterson
Phone: [phone] ext:400
E-mail: [e-mail]
Web Address: www.LifePointInc.com

LifePoint, Inc., a leader in non-invasive drug diagnostic technologies
and solutions, has developed, manufactures and markets the IMPACT(R)
Test System - a rapid diagnostic testing, screening and drug
monitoring device for use in law enforcement and the workplace, and in
the future, ambulances, pharmacies, and home healthcare markets.
LifePoint's patented and proprietary technologies for the use of
saliva as a non-invasive, blood-comparable test specimen, used in
conjunction with the flow immunosensor technology licensed from the
United States Navy, have allowed LifePoint to develop a broadly
applicable, rapid, on-site diagnostic test system. The first product
simultaneously detects drugs of abuse and alcohol. The initial three
target markets - law enforcement, industrial workplace and medical
emergency room - are estimated to be over $1.6 billion in total
opportunity.

Company: Lorantis Ltd
Web Address: www.lorantis.com

Lorantis, located in Cambridge, UK is developing a pipeline of
therapeutics for the treatment of disease using its proprietary
antigen-specific immune therapy (ASPECT(TM)) platforms. These products
will treat underlying disease by the selective antigen-specific up or
down regulation of immune responses through targeting Notch, a
receptor present on T-cells, without affecting normal protective
immunity. Products will be developed for allergy, autoimmune disease,
transplant rejection, infectious disease and cancer. The company's
mission is to advance key products over the next three years from
their current pre-clinical state to clinical proof of principle, where
they will be partnered. Other products generated will be partnered
from pre-clinical testing. First introduction in humans is planned in
2004, with initial proof of efficacy in 2005.

Company: MacroPore Biosurgery
Ticker Symbol: XMP (Frankfurt Stock Exchange in Germany)
Workshop: Small-Cap/Listed Companies Session
Media Contact: Christopher J. Calhoun
Investor Relations Contact: Ari Bisimis
Phone: [phone]
E-mail: [e-mail]
Company URL: www.macropore.com

Product description: Bioresorbable polymer surgical implants which are
naturally resorbed and metabolized by the body. Hydrosorb(TM)
bioresorbable products, used for spinal and reconstructive
indications, are distributed by Medtronic. SurgiWrap(TM) bioresorbable
thin film is used for soft tissue support. Through its biologics
technology, the company isolates adult stem cells from adipose (fat)
tissues.
Company description: With headquarters located in San Diego, CA,
MacroPore Biosurgery develops and markets products categorized in the
biosurgery market. Biomaterials platform technology includes
bioresorbable products that aid in the reconstruction, repair and
regeneration of bone and soft tissue throughout the body, and
biologics (stem cells) represent a second platform technology.

Company: Micromet AG
Public Relations Contact: Evelyn Wolf
Investor Relations Contact: Ines-Regina Buth
Phone: [phone]
E-mail: [e-mail] / [e-mail]
Web Address: www.micromet.de

Micromet is a private drug development company that puts novel
concepts in immunotherapy to work. Using proprietary technologies, the
Company creates and develops drugs against cancer, inflammation and
autoimmunity. With its bispecific T cell engager (BiTE(TM)) platform,
Micromet employs a unique approach to eliminate pathogenic cells by
engaging large numbers of T cells. Micromet has integrated
infrastructure and strong expertise in all disciplines ranging from
drug design to clinical development. Two of its products are currently
in clinical trials. The Company has attracted both top-tier life
science investors and corporate partners such as MedImmune, Inc.,
Novuspharma SpA and Enzon, Inc.

Company: Nuevolution A/S
Public Relations Contact: Soeren Buur
Investor Relations Contact: Zahed Subhan
Phone: [phone]
E-mail: [e-mail] / [e-mail] /
[e-mail]
Web Address: www.nuevolution.com

Nuevolution is a unique drug discovery company poised to revolutionize
drug discovery and development by utilizing its proprietary
Chemetics(TM) technology to cost-effectively generate tens to hundreds
of potent, structurally diverse, small molecule clinical candidates to
virtually any target in a matter weeks. Chemetics(TM) is an innovative
system in which molecular biological approaches are combined with
proven wet chemistry allowing in a single test tube, the synthesis of
DNA-templated small molecule libraries of unprecedented diversity and
size (up to 1014 compounds), and the subsequent selection of
highest-affinity new chemical entities. Chemetics(TM) is being
developed to the point where it is expected that some trillion
compounds may be synthesized and subjected to accurate selection in
less than a month.

Company: Opexa Pharmaceuticals, Inc.
Public Relations Contact: Michael T. Redman
Investor Relations Contact: Michael T. Redman
Phone: [phone]
E-mail: [e-mail]
Web Address: www.opexapharma.com

Opexa Pharmaceuticals, Inc., founded in 2001, is engaged in the
development of therapeutics for autoimmune diseases and graft
rejection. The company's lead product, Tovaxin, is currently being
evaluated in a Phase I/II dose-escalation trial under an IND approved
by the FDA. To date, more than 130 patients have been treated with
Tovaxin. Opexa anticipates that Tovaxin will be a chronic treatment
dosed subcutaneously twice per year. The underlying technology of
Tovaxin is T cell vaccination. Tovaxin has been shown to deplete
myelin-reactive T cells, the underlying cause of MS.

Company: Perlegen Sciences, Inc.
Public Relations Contact: Philip N. Sussman
Investor Relations Contact: Philip N. Sussman
Phone: [phone]
E-mail: [e-mail]
Web Address: www.perlegen.com

Perlegen Sciences, Inc. is a private Mountain View, California-based
company that was spun off from Affymetrix, Inc. three years ago.
Perlegen has collaborations with companies such as GlaxoSmithKline,
Bristol-Myers Squibb, Pfizer, Eli Lilly, and Unilever, to conduct
research into how variation in genes and regulatory sequences are
associated with disease, drug response, and other traits. Through
these collaborations, Perlegen is accelerating the discovery and
development of pharmaceutical and diagnostic products. Additionally,
Perlegen is moving rapidly toward the in-licensing and clinical
development of late-stage drug candidates that have been blocked in
development and where the pharmaceutical companies developing them
have observed possible genetic differences in patients' response.

Company: Rejuvenon Corp
Public Relations Contact: Brandon Lewis
Investor Relations Contact: Brandon Lewis
Phone: [phone]
E-mail: [e-mail]
Web Address: www.rejuvenon.com

Rejuvenon Corp. ("Rejuvenon" or "the Company") is a private
biopharmaceutical company committed to developing and commercializing
promising compounds that are ready for clinical or preclinical
testing. Rejuvenon's drug development team has collectively helped to
bring over 60 approved drugs to market and includes three former
vice-presidents of Merck whose responsibilities ranged from research,
to safety assessment, to process research and development. The Company
deploys its breadth of experience in drug development and a wealth of
contacts in the pharmaceutical industry to select early stage
compounds that are most attractive for commercialization. The
Company's first portfolio of novel compounds, a collection of
orally-deliverable, small molecular ghrelin agonists, are in Phase I
human clinical studies for cancer cachexia or wasting, a condition
that affects an estimated 80% of patients diagnosed with neoplastic
disease. Current treatments for this condition are utilized in only a
relatively small percentage of patients and are very limited in their
therapeutic effect. On the other hand, studies with ghrelin and
agonists of its associated G-protein coupled receptor have been shown
to stimulate appetite and reverse nitrogen loss, which management
believes will translate into a substantial market opportunity.

Company: Salmedix, Inc.
Public Relations Contact: Anita Busquets
Phone: [phone]
E-mail: [e-mail]
Web Address: www.salmedix.com

Salmedix, Inc. is developing a portfolio of three oncology drugs in
Phase II clinical trials with an initial commercial focus on
hematologic cancers. We have implemented strategies to improve the
probability of success and reduce the cost of drug development by
developing compounds that have prior human clinical experience.
SDX-105, our lead Phase II/III product, is a proven cytotoxic agent
with a distinct activity profile which is marketed in Germany. We are
developing SDX-105 for non-Hodgkin's lymphoma and CLL. SDX-101 is in
Phase II for CLL. SDX-102 is in Phase II for non-small cell lung
cancer and pancreatic cancer.

Company: TeGenero AG
Public Relations Contact: Dr. Benedikte Hatz
Investor Relations Contact: Dr. Benedikte Hatz
Phone: [phone]
E-mail: [e-mail]
Web Address: www.tegenero.com

TeGenero is dedicated to the identification and development of
innovative, highly effective and broadly applicable
immunotherapeutics. The landmark discovery of a unique class of
"superagonistic" antibodies - SuperMAB(R) - that stimulate the
generation of T lymphocytes as key regulators of an immune response,
led to TeGenero's first product candidate, which is far advanced in
pre-clinical development. Concomitantly, TeGenero is generating a
pipeline of novel therapeutics. Clinical applications of SuperMAB(R)
are expected to solve unmet medical needs in cancer-related
immunodeficiencies and autoimmune diseases. Since its inception,
TeGenero raised EUR 10.6 million from Bear Stearns Health
Innoventures, HBM BioVentures, BioM Venture and BioMAG.

Company: Trigen Ltd
Public Relations Contact: Katharine Harris
Investor Relations Contact: Katharine Harris
Phone: [phone]
E-mail: kharris@trigen/co.uk
Web Address: www.trigen.co.uk

Trigen is a private UK biotechnology company, based in London,
discovering and developing novel drugs for the management of occlusive
and inflammatory cardiovascular diseases. Trigen has innovative,
intravenous and oral anti-coagulant, direct thrombin inhibitors in
clinical studies from its lead drug development programme. In
addition, Trigen has other programmes focused on thrombosis and
ischaemia-related diseases in preclinical development. Trigen was
founded in 1992 to invest in and develop the drug discovery
technologies of the world-renowned Thrombosis Research Institute (TRI)
in London.

Company: Vecta Ltd.
Public Relations Contact: Dr. Michael Marash
Investor Relations Contact: Dr. Sabina Glozman
Phone: [phone]
E-mail: [e-mail]

Company Profile: Vecta Ltd. is an R&D-based pharmaceutical company
dedicated to the development of innovative solutions in
gastroenterology. Vecta was founded in Israel in May 2001. The
Company's vision is to become a leading provider of innovative
solutions in the field of gastroenterology and narrow spectrum
antibiotics, by capitalizing on the existing treatment pitfalls and
unmet clinical needs. The new solutions provided by Vecta offer
physicians and patients a new option for curing the major causes of
Peptic Ulcers, i.e. Helicobacter pylori (H. pylori) and amplified acid
secretion, and thereby provides a beneficial alternative to the
currently marketed products. Vecta is currently beginning Ph I-IIa of
Clinical Trials in Israel.